Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

HER2 positive gastroesophageal cancer

Targeting HER2 in operable gastroesophageal cancer

Date

20 Oct 2023

Session

HER2 positive gastroesophageal cancer

Topics

Cancer Biology;  Targeted Therapy;  Immunotherapy;  Surgical Oncology

Tumour Site

Gastric Cancer;  Gastro-Oesophageal Junction Cancer

Presenters

Florian Lordick

Authors

F. Lordick

Author affiliations

  • Medicine Department, Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, 04103 - Leipzig/DE

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.